Rachel Freedman, MD, on CDK4/6 Therapy for Patients With Early Breast Cancer
An ASCO expert panel offered new guidance on cyclin-dependent kinase 4 and 6 (CDK4/6) adjuvant therapy for patients with early breast cancer. As the panel noted in the rapid recommendation update published in the , the new guidance for abemaciclib (Verzenio) was based on a new of the monarchE trial that included 5-year efficacy outcomes.